Quanterix (NASDAQ:QTRX) reported quarterly sales of $26.70 million which beat the analyst consensus estimate of $24.01 million by 11.20 percent. This is a 14.94 percent decrease over sales of $31.39 million the same period last year.
Lexicon Submits New Drug Application For Sotagliflozin For Treatment Of Heart Failure In Adults With Type 2 Diabetes
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of sotagliflozin to
